Dmytro Kharkov

Eli Lilly wins U.S. approval for once-weekly type 2 diabetes insulin

Eli Lilly wins U.S. approval for once-weekly type 2 diabetes insulin
Weekly insulin gains approval

Adults with type 2 diabetes in the U.S. are set to gain a new treatment option after Eli Lilly secured clearance for its once-weekly basal insulin, Onswik. The approval adds an alternative to daily long-acting insulin injections and positions Lilly more directly against other makers expanding in the diabetes market.

Highlights

  • Eli Lilly received U.S. FDA approval for Onswik, a once-weekly insulin for adults with type 2 diabetes, aiming to reduce injection frequency by over 300 shots annually.
  • Onswik will launch in the U.S. in the coming months as a pre-filled KwikPen in 500 and 1,000 units per milliliter concentrations, following positive results in a 3,400-patient late-stage trial program.
  • The approval expands Onswik's global reach and intensifies U.S. competition with Sanofi's Lantus, Lilly's Basaglar, and Novo Nordisk's newly approved Awiqli.

Approval details and launch plan

As reported by Reuters, citing Eli Lilly, the U.S. Food and Drug Administration has approved Onswik, chemically known as insulin efsitora alfa-gobe, for adults with type 2 diabetes. The company says the treatment is intended to be used alongside diet and exercise to help control high blood sugar.

Lilly says the once-weekly therapy could cut injection frequency by more than 300 shots a year compared with once-daily basal insulin. The drugmaker adds that Onswik will be available in the United States in the coming months as a pre-filled KwikPen in two concentrations, 500 units per milliliter and 1,000 units per milliliter.

The regulatory decision is based on a late-stage trial program involving more than 3,400 adults with type 2 diabetes across four studies. In those studies, Onswik meets the main goal each time, showing A1C reductions that are not inferior to daily basal insulins glargine.

Competitive context and patient limits

Insulin glargine, sold under brands including Sanofi's Lantus and Lilly's Basaglar, is a long-acting man-made insulin used to manage blood sugar in people with type 1 and type 2 diabetes. Lilly says Onswik should not be used in patients with type 1 diabetes because of an increased risk of severe hypoglycemia, or dangerously low blood sugar.

The approval also extends Onswik's regulatory footprint after earlier clearances in Europe, Japan and Mexico. In March, the U.S. FDA also approved Novo Nordisk's Awiqli for blood sugar control in adults living with type 2 diabetes, adding to competition in the long-acting insulin segment.

Our earlier coverage of Novo Nordisk’s plan to launch more than five potential blockbuster drugs by 2030 examined the company’s push to reassure investors as competitive pressure rises and semaglutide exclusivity eventually fades. We noted that while management is trying to broaden its pipeline beyond diabetes and obesity into areas like cardiovascular, liver, and blood disorders, the market is focused on execution and tangible progress rather than headline targets.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.